Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (83) clinical trials

Patients are needed to participate in a clinical research study of paclitaxel, everolimus, ibrutinib, cetuximab, docetaxel

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination treatment of ibrutinib with everolimus, paclitaxel, docetaxel, or cetuximab in selected advanced gastrointestinal and genitourinary tumors.


Patients are needed to participate in a clinical research study for the treatment of Colorectal Cancer, head and neck cancer, bladder cancer, Carcinoma, Squamous Cell of Head and Neck, Renal Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Adenocarcinoma

This is a phase 1, open-label, multicenter, dose escalation study that will examine the safety profile of SGN-2FF given orally to patients with advanced solid tumors. The primary goal of the study is to identify the maximum tolerated dose (MTD), or optimal biological dose (OBD) that does not exceed the ...


A Phase 1b/2 Study of MEDI4736 With Tremelimumab MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma


A clinical trial seeking patients for a research study for the treatment of Renal Cell Carcinoma

A post marketing data collection of a cryosurgical system [PROSENSE] of IceCure Medical], for the treatment of renal cell carcinoma (RCC).


A Phase 3 clinical study for patients with Deleterious BRCA2 Gene Mutation, Recurrent Ovarian Carcinoma, Ovarian Seromucinous Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Endometrioid Tumor, Recurrent Fallopian Tube Carcinoma, BRCA Rearrangement, Ovarian Clear Cell Adenocarcinoma, Undifferentiated Fallopian Tube Carcinoma, Ovarian Serous Tumor, Fallopian Tube Clear Cell Adenocarcinoma, Deleterious BRCA1 Gene Mutation

PRIMARY OBJECTIVES: I. Assess the efficacy of either single agent olaparib or the combination of cediranib (cediranib maleate) and olaparib, as measured by progression free survival (PFS), as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer. SECONDARY OBJECTIVES: I. Assess ...


A clinical trial to evaluate treatments using Pembrolizumab for patients with Adrenocortical carcinoma

Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.


Patients are needed to participate in a clinical research study for the treatment of Ductal Carcinoma In Situ, Postmenopausal

PRIMARY OBJECTIVES; I. To assess whether CE/BZA (conjugated estrogens/bazedoxifene) for 28 days +/- 7 days reduces proliferation as measured by marker of proliferation Ki-67 (Ki-67) protein expression. SECONDARY OBJECTIVES: I. To assess whether CE/BZA alters markers associated with progression to invasive cancer (abrogated response to cellular stress [ARCS] signature) in ...


Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

The trial is being done in three parts: Part 1A (MEL and RCC) will define the maximum tolerated dose (MTD)/maximum administered dose (MAD) for the drug combinations; a recommended Phase 2 dose (RP2D) for each combination will be identified. Part 1B (MEL-single arm expansion) will better characterize safety and efficacy ...


Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Stage I - Pharmacokinetics (Bioequivalence) Subjects will be randomized to receive CC-486 300 mg orally on each of the two pharmacokinetic (PK) study days based on the dosing sequences they are randomized to: Dosing Sequence 1: 2x150 mg tablets followed by 1x30 mg tablet. Dosing Sequence 2: 1x300 mg tablet ...